汇宇制药：注射用HY0001aⅠ期临床试验完成首例受试者给药

Core Viewpoint - Huiyu Pharmaceutical (688553) announced that its wholly-owned subsidiary, Huiyu Haiyue, has initiated a Phase I clinical trial for its self-developed innovative biological drug, HY0001a, aimed at treating advanced solid tumors, with the first patient successfully dosed recently [1] Company Summary - Huiyu Pharmaceutical's subsidiary, Huiyu Haiyue, is responsible for the development of the innovative drug HY0001a [1] - The drug is classified as a Class I biological innovative drug [1] - The clinical trial is focused on advanced solid tumors, indicating a strategic move into a critical area of oncology [1]